TargetCancer Foundation

- Founded in 2009 by Paul Poth, a dedicated husband, new dad, and lawyer with a passion for public service.
- Diagnosed at the age of 38 with cholangiocarcinoma, a rare cancer that had no treatment or cure and very little research dedicated to it.
- The only option was a best-guess treatment approach that relied on protocols developed for other cancers — all debilitating but none effective.
- Paul started Target Cancer Foundation and raised funds for their first research investment – $7,500
- Paul's wife (Kristen Poth) and brother in-law (Jim Palma) continued the fight

What began as an effort to fund basic research in rare cancers like cholangiocarcinoma and esophageal cancer has evolved into an organization that tackles challenges shared across all rare cancers, offering new options and support for everyone living with a rare cancer.

TargetCancer Foundation

TargetCancer Foundation

November 2023 Think Tank Event

MAX VINCZE FOUNDATION

Maximizing Impact Through Rare Young Adult Cancer Research.℠

November 2023

The Think Tank on Advancing Precision Medicine in Rare Cancers

Max Vincze Foundation was invited to this:

- highly interactive, one-day meeting held in Boston
- uniting clinicians, researchers, industry, regulators, patient advocates, and patients across the rare cancer community.

What is TRACK?

Developed and launched by TargetCancer Foundation, TCF-001 TRACK is a **fully remote** clinical trial enrolling 400 patients with rare cancers or cancers of unknown primary.

Through a **remote consenting process**, patients can enroll in the TRACK study from their homes, without traveling to a clinical trial site.

TRACK

TARGET → RARE → CANCER → KNOWLEDGE



> One of TargetCancer Foundation's greatest strengths is its power to convene the brightest minds in rare cancer science and spark paradigm-shifting research that directly benefits patients.

Razelle Kurzrock, MD

Froedtert and Medical College of Wisconsin

VIRTUAL MOLECULAR TUMOR BOARD (VMTB)

- medical oncologists, surgeons, pathologists, genetic counselors, and others who specialize in rare cancers and are experts in interpreting the **biomarker** testing reports that a TRACK patient receives.

- The group meets weekly and reviews each patient’s case for an in-depth discussion of their medical history and individual biomarker testing reports to offer personalized treatment recommendations for difficult-to-treat cancers.

- Access to the VMTB allows **patients anywhere in the country** to have experienced physicians and experts in rare tumors review their case, which is especially important for patients treated outside of major academic centers, who may not have access to specialists in their rare cancer.

TRACK

TARGET → RARE → CANCER → KNOWLEDGE

TRACK

TARGET → RARE → CANCER → KNOWLEDGE

Additional benefits and details:

- A medical acquisition specialist who is very effective in helping patients secure insurance reimbursement or compassionate use for medications.

- Genetic counselors to advise on testing, screening, and inherited cancers.

- Limitation of the study is that they don’t provide actual treatments- they instead make recommendations which would then need to be implemented by the treating physician, however they do provide support through that process.

Thank You!

TargetCancer
Foundation

TRACK

TARGET → RARE → CANCER → KNOWLEDGE

targetcancerfoundation.org

info@targetcancerfoundation.org